AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33640346 — intervention group
Group type: COMPARATOR
Intervention: Biventricular pacing (BiV)
Number of subjects: 19
Study 33640346 — intervention group
Group type: COMPARATOR
Intervention: His bundle pacing (HBP)
Number of subjects: 19
Study 33640423 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton therapy (PT)
Number of subjects: 0
Study 33640423 — intervention group
Group type: COMPARATOR
Intervention: Intensity modulated radiation therapy (IMRT)
Number of subjects: 0
Study 33640423 — intervention group
Group type: COMPARATOR
Intervention: Stereotactic body proton therapy (SBPT)
Number of subjects: 0
Study 33640521 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-centered opioid prescription guidelines
Number of subjects: 229
Study 33640521 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonopioid analgesics
Number of subjects: 229
Study 33640521 — intervention group
Group type: EXPERIMENTAL
Intervention: FDA-compliant disposal methods
Number of subjects: 229
Study 33640521 — intervention group
Group type: EXPERIMENTAL
Intervention: Convenient drop-box for disposal
Number of subjects: 229
Study 33640521 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescribed pills
Number of subjects: 229
Study 33640578 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-treatment FDG-PET and DWI-MR imaging parameters
Number of subjects: 33
Study 33640865 — intervention group
Group type: EXPERIMENTAL
Intervention: Hudl Technique app with telehealth
Number of subjects: 45
Study 33640865 — intervention group
Group type: COMPARATOR
Intervention: Standard HEPs on paper without feedback (control)
Number of subjects: 45
Study 33640865 — intervention group
Group type: COMPARATOR
Intervention: Comparison between experimental and control groups
Number of subjects: 45
Study 33640871 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribociclib 300 mg three weeks in a row with a 1 week break and everolimus 2.5 mg daily (first 12 patients)
Number of subjects: 21
Study 33640871 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribociclib 200 mg and everolimus 2.5 mg daily (additional 9 patients)
Number of subjects: 21
Study 33640871 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ribociclib and everolimus
Number of subjects: 21
Study 33641042 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthracycline-based therapy
Number of subjects: 0
Study 33641042 — intervention group
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Number of subjects: 0
Study 33641042 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide
Number of subjects: 0
Study 33641042 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft tissue sarcoma regimens
Number of subjects: 0
Study 33641042 — intervention group
Group type: EXPERIMENTAL
Intervention: NF1-associated MPNST
Number of subjects: 0
Study 33641083 — intervention group
Group type: EXPERIMENTAL
Intervention: HP (trastuzumab + pertuzumab)
Number of subjects: 948
Study 33641083 — intervention group
Group type: COMPARATOR
Intervention: H without P (trastuzumab without pertuzumab)
Number of subjects: 948
Study 33641083 — intervention group
Group type: COMPARATOR
Intervention: No H (no trastuzumab)
Number of subjects: 948
Study 33641083 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 948
Study 33641211 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixazomib (MLN9708) 4 mg in combination with Fulvestrant
Number of subjects: 9
Study 33641211 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixazomib (MLN9708) and Fulvestrant
Number of subjects: 9
Study 33641356 — intervention group
Group type: EXPERIMENTAL
Intervention: Inorganic Nitrite Supplementation
Number of subjects: 0
Study 33641356 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 33641372 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotational atherectomy
Number of subjects: 0
Study 33641372 — intervention group
Group type: COMPARATOR
Intervention: Modified balloons
Number of subjects: 0
Study 33641374 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-Month Dual Antiplatelet Therapy
Number of subjects: 0
Study 33641374 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 33641385 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular therapy (EVT) performed in 49 patients (32.7%; mechanical thrombectomy, n=43)
Number of subjects: 150
Study 33641385 — intervention group
Group type: COMPARATOR
Intervention: Medical management
Number of subjects: 150
Study 33641670 — intervention group
Group type: EXPERIMENTAL
Intervention: Aortic valve replacement (AVR)
Number of subjects: 41
Study 33641670 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 41
Study 33641678 — intervention group
Group type: EXPERIMENTAL
Intervention: HC-INR
Number of subjects: 20
Study 33641678 — intervention group
Group type: EXPERIMENTAL
Intervention: HC-ACT+
Number of subjects: 20
Study 33641678 — intervention group
Group type: EXPERIMENTAL
Intervention: HC-ACT-LR
Number of subjects: 20
Study 33641678 — intervention group
Group type: EXPERIMENTAL
Intervention: HC-aPTT
Number of subjects: 20
Study 33641678 — intervention group
Group type: EXPERIMENTAL
Intervention: ROC curve
Number of subjects: 20
Study 33641772 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Number of subjects: 0
Study 33641772 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 0
Study 33643204 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital therapeutic for speech, language, and cognitive intervention
Number of subjects: 0
Study 33643689 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT) 6 or 8 Gy x 2 or 3 doses followed by 4 cycles of ipilimumab
Number of subjects: 22
Study 33643689 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT) followed by ipilimumab
Number of subjects: 22
Study 33643689 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy followed by ipilimumab
Number of subjects: 22
Study 33643905 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocrine Therapy (ET)
Number of subjects: 2342
Study 33643905 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (CT)
Number of subjects: 2342
Study 33643905 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative ET
Number of subjects: 2342
Study 33643905 — intervention group
Group type: EXPERIMENTAL
Intervention: First line ET
Number of subjects: 2342
Study 33643905 — intervention group
Group type: EXPERIMENTAL
Intervention: Second line ET
Number of subjects: 2342
Study 33643905 — intervention group
Group type: EXPERIMENTAL
Intervention: Third line ET
Number of subjects: 2342
Study 33643905 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatase inhibitor (AI) monotherapy
Number of subjects: 2342
Study 33643905 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus plus AI regimen
Number of subjects: 2342
Study 33643965 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 33644082 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 0
Study 33644082 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo or standard care)
Number of subjects: 0
Study 33644099 — intervention group
Group type: EXPERIMENTAL
Intervention: Furin expression levels in patients with psoriasis
Number of subjects: 0
Study 33644235 — intervention group
Group type: EXPERIMENTAL
Intervention: IgG quantification against S1-RBD of SARS-CoV-2
Number of subjects: 639
Study 33644235 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutralizing antibody quantification using ELISA and luminescent SARS-CoV-2 pseudotype
Number of subjects: 639
Study 33644492 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic monitoring devices (EMDs) linked to a mobile application (app) for ICS and rescue inhalers
Number of subjects: 75
Study 33644492 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (controls)
Number of subjects: 75
Study 33644492 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic monitoring devices (EMDs)
Number of subjects: 75
Study 33644749 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training
Number of subjects: 0
Study 33644749 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 0
Study 33644749 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination training
Number of subjects: 0
Study 33644749 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 0
Study 33644759 — intervention group
Group type: COMPARATOR
Intervention: Calorie restriction (CR)
Number of subjects: 0
Study 33644812 — intervention group
Group type: EXPERIMENTAL
Intervention: Handgrip force
Number of subjects: 20
Study 33644812 — intervention group
Group type: EXPERIMENTAL
Intervention: MIP
Number of subjects: 20
Study 33644812 — intervention group
Group type: EXPERIMENTAL
Intervention: MEP
Number of subjects: 20
Study 33645542 — intervention group
Group type: EXPERIMENTAL
Intervention: PLD1 variants
Number of subjects: 30
Study 33645542 — intervention group
Group type: EXPERIMENTAL
Intervention: PLD1 inhibition
Number of subjects: 30
Study 33646153 — intervention group
Group type: EXPERIMENTAL
Intervention: UPSIT (University of Pennsylvania Smell Identification Test)
Number of subjects: 54
Study 33646302 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA-haploidentical HSCT with age-adapted myeloablative conditioning and T-cell immunotherapy
Number of subjects: 50
Study 33646302 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA-haploidentical HSCT
Number of subjects: 50
Study 33646505 — intervention group
Group type: EXPERIMENTAL
Intervention: Olfactory and gustatory dysfunctions (OGD)
Number of subjects: 5868
Study 33646820 — intervention group
Group type: EXPERIMENTAL
Intervention: Entrectinib
Number of subjects: 161
Study 33647009 — intervention group
Group type: EXPERIMENTAL
Intervention: Infection Manager System (IMS)
Number of subjects: 914
Study 33647009 — intervention group
Group type: COMPARATOR
Intervention: C-reactive protein (CRP) at ≥20mg/L
Number of subjects: 914
Study 33647009 — intervention group
Group type: COMPARATOR
Intervention: Procalcitonin (PCT) at 0.5 ng/ml
Number of subjects: 914
Study 33647333 — intervention group
Group type: COMPARATOR
Intervention: Electroencephalogram (EEG) frequency bands: SMR (12-15 Hz), beta (14.5-30 Hz), beta I (14.5-20 Hz), beta II (20-25 Hz), beta III (25-30 Hz), gamma I (31-49 Hz)
Number of subjects: 402
Study 33647530 — intervention group
Group type: EXPERIMENTAL
Intervention: HABIT-ILE (hand-arm bimanual intensive therapy including lower extremities)
Number of subjects: 25
Study 33647548 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial irinotecan (Arm B)
Number of subjects: 421
Study 33647548 — intervention group
Group type: COMPARATOR
Intervention: Sequential irinotecan (Arm A)
Number of subjects: 421
Study 33647913 — intervention group
Group type: COMPARATOR
Intervention: Renal Autologous Cell Therapy (REACT); 2 doses at 6-month intervals
Number of subjects: 5
Study 33647987 — intervention group
Group type: EXPERIMENTAL
Intervention: Monopolar hypoglossal nerve stimulation (HNS)
Number of subjects: 0
Study 33647987 — intervention group
Group type: EXPERIMENTAL
Intervention: Guarded bipolar hypoglossal nerve stimulation (HNS)
Number of subjects: 0
Study 33647987 — intervention group
Group type: EXPERIMENTAL
Intervention: Grouped cathode and single cathode configurations
Number of subjects: 0
Study 33647987 — intervention group
Group type: EXPERIMENTAL
Intervention: Monopolar configurations
Number of subjects: 0
Study 33648577 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% povidone-iodine solution
Number of subjects: 135
Study 33648577 — intervention group
Group type: COMPARATOR
Intervention: 4% chlorhexidine gluconate solution
Number of subjects: 135
Study 33648577 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 135
Study 33649343 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Number of subjects: 3500
Study 33649343 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3500
Study 33649760 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular plasma prophylaxis
Number of subjects: 87
Study 33649760 — intervention group
Group type: COMPARATOR
Intervention: No regular plasma prophylaxis
Number of subjects: 87
Study 33649760 — intervention group
Group type: EXPERIMENTAL
Intervention: Children <10 years of age
Number of subjects: 87
Study 33649760 — intervention group
Group type: COMPARATOR
Intervention: Patients >40 years of age
Number of subjects: 87
Study 33650179 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly carfilzomib (20/70 mg/m²), cyclophosphamide, and dexamethasone (wKCd)
Number of subjects: 0
Study 33650259 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-world data (RWD) from NHANES and longitudinal data from elagolix phase III clinical trials
Number of subjects: 0
Study 33650294 — intervention group
Group type: EXPERIMENTAL
Intervention: Etonogestrel pharmacokinetic and pharmacodynamic outcomes based on genetic ancestry (EUR, AFR, AMR)
Number of subjects: 350
Study 33650294 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum etonogestrel concentrations
Number of subjects: 350
Study 33650294 — intervention group
Group type: EXPERIMENTAL
Intervention: Progestin-related side effects (bothersome bleeding and subjective weight gain)
Number of subjects: 350
Study 33650449 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 33650781 — intervention group
Group type: EXPERIMENTAL
Intervention: Single bout of moderate-intensity exercise (treadmill walking, expending 500 kcal at 60%-70% VO2 max)
Number of subjects: 42
Study 33650967 — intervention group
Group type: EXPERIMENTAL
Intervention: TLR7 deleterious variants in severely affected males (2.1%)
Number of subjects: 156
Study 33650967 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional gene expression profile analysis
Number of subjects: 156
Study 33650967 — intervention group
Group type: EXPERIMENTAL
Intervention: TLR7 loss-of-function variants
Number of subjects: 156
Study 33650972 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive behavior therapy
Number of subjects: 19
Study 33650998 — intervention group
Group type: EXPERIMENTAL
Intervention: Deceased donor liver transplantation (DDLT) for patients with HCC and hilar CCA (hCCA) with an exception score of median MELD score at transplant (MMAT)-3.
Number of subjects: 0
Study 33650998 — intervention group
Group type: EXPERIMENTAL
Intervention: Deceased donor liver transplantation (DDLT) and living donor liver transplantation (LDLT) for iCCA and CRLM.
Number of subjects: 0
Study 33651116 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of 37 MBq (± 10%)
Number of subjects: 10
Study 33651243 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil infusion with conversation
Number of subjects: 0
Study 33651243 — intervention group
Group type: COMPARATOR
Intervention: Remifentanil infusion in a quiet environment
Number of subjects: 0
Study 33651243 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil infusion
Number of subjects: 0
Study 33651368 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 363919
Study 33651368 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 363919
Study 33651368 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 363919
Study 33651368 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 363919
Study 33651630 — intervention group
Group type: EXPERIMENTAL
Intervention: Training overload (TO) phase for 4 weeks followed by a 2-week recovery, with running volume at 131 ± 3% of baseline during TO and 63 ± 6% during recovery.
Number of subjects: 16
Study 33651630 — intervention group
Group type: COMPARATOR
Intervention: Well-adapted (WA) runners (control group).
Number of subjects: 16
Study 33651744 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 277
Study 33651744 — intervention group
Group type: EXPERIMENTAL
Intervention: RFM
Number of subjects: 277
Study 33651744 — intervention group
Group type: EXPERIMENTAL
Intervention: WC
Number of subjects: 277
Study 33652270 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine anesthesia
Number of subjects: 11
Study 33652270 — intervention group
Group type: COMPARATOR
Intervention: Etomidate anesthesia
Number of subjects: 11
Study 33653216 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction with fludarabine, cyclophosphamide, and ofatumumab; consolidation with 4 doses of ofatumumab for MRD+ patients
Number of subjects: 28
Study 33653216 — intervention group
Group type: COMPARATOR
Intervention: No intervention for MRD- patients
Number of subjects: 28
Study 33653216 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment (including induction and consolidation)
Number of subjects: 28
Study 33653294 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard practice treatment according to the center
Number of subjects: 6000
Study 33653374 — intervention group
Group type: EXPERIMENTAL
Intervention: CPS-mandated treatment
Number of subjects: 245
Study 33653374 — intervention group
Group type: COMPARATOR
Intervention: Stress score increase
Number of subjects: 245
Study 33653374 — intervention group
Group type: COMPARATOR
Intervention: Co-occurring mental health diagnosis
Number of subjects: 245
Study 33653394 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight management intervention
Number of subjects: 16
Study 33653910 — intervention group
Group type: EXPERIMENTAL
Intervention: Very elderly subjects (age ≥ 80 years)
Number of subjects: 5557
Study 33653910 — intervention group
Group type: COMPARATOR
Intervention: Elderly subjects (age < 80 years)
Number of subjects: 5557
Study 33653910 — intervention group
Group type: EXPERIMENTAL
Intervention: Age as a risk factor
Number of subjects: 5557
Study 33654016 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 0
Study 33654090 — intervention group
Group type: EXPERIMENTAL
Intervention: BBV152 vaccine candidate (three different formulations) administered at 0 and 14 days
Number of subjects: 20
Study 33654090 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 33654117 — intervention group
Group type: EXPERIMENTAL
Intervention: Human intravital microscopy (HIVM)
Number of subjects: 30
Study 33654407 — intervention group
Group type: EXPERIMENTAL
Intervention: TEAM intervention (curriculum-guided self-management approach using peer dyads)
Number of subjects: 160
Study 33654407 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 160
Study 33654425 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine topical system 1.8%
Number of subjects: 125
Study 33654425 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine patch 5%
Number of subjects: 125
Study 33654425 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine medicated plaster 5%
Number of subjects: 125
Study 33654425 — intervention group
Group type: COMPARATOR
Intervention: Generic lidocaine patch 5%
Number of subjects: 125
Study 33655197 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrous sulfate heptahydrate (FeSO)
Number of subjects: 0
Study 33655197 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33655364 — intervention group
Group type: EXPERIMENTAL
Intervention: PTFE grafts during pancreatectomy
Number of subjects: 19
Study 33655413 — intervention group
Group type: EXPERIMENTAL
Intervention: Everion® wearable device (WD) for 14 days
Number of subjects: 20
Study 33655551 — intervention group
Group type: EXPERIMENTAL
Intervention: Athletes
Number of subjects: 112
Study 33655551 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 112
Study 33655675 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium alginate hydrogel sealant
Number of subjects: 20
Study 33655723 — intervention group
Group type: EXPERIMENTAL
Intervention: AHREs >6 minutes
Number of subjects: 816
Study 33655723 — intervention group
Group type: EXPERIMENTAL
Intervention: LA diameter >41 mm
Number of subjects: 816
Study 33655723 — intervention group
Group type: EXPERIMENTAL
Intervention: Sick sinus syndrome
Number of subjects: 816
Study 33655941 — intervention group
Group type: EXPERIMENTAL
Intervention: Adipose tissue MSC obtained by enzymatic method
Number of subjects: 100
Study 33655941 — intervention group
Group type: COMPARATOR
Intervention: Mechanically fragmented adipose tissue
Number of subjects: 100
Study 33655955 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia (EA)
Number of subjects: 400
Study 33655955 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia (EA1 group, CDE < 3 cm)
Number of subjects: 400
Study 33655955 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia (EA2 group, 3 cm ≤ CDE < 6 cm)
Number of subjects: 400
Study 33655971 — intervention group
Group type: EXPERIMENTAL
Intervention: Interlaminar epidural steroid injection (ILESI)
Number of subjects: 65
Study 33655979 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic tongue diagnosis system (ATDS)
Number of subjects: 0
Study 33655979 — intervention group
Group type: COMPARATOR
Intervention: Healthy group (control)
Number of subjects: 0
Study 33656448 — intervention group
Group type: EXPERIMENTAL
Intervention: FASST intervention (n=20)
Number of subjects: 30
Study 33656448 — intervention group
Group type: COMPARATOR
Intervention: Control condition (basic app with educational resources; n=10)
Number of subjects: 30
Study 33656471 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported psychiatric history
Number of subjects: 272
Study 33656471 — intervention group
Group type: EXPERIMENTAL
Intervention: Concussion diagnosis
Number of subjects: 272
Study 33656471 — intervention group
Group type: EXPERIMENTAL
Intervention: History of previous concussion
Number of subjects: 272
Study 33656471 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval from injury to ED presentation
Number of subjects: 272
Study 33656536 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA-haploidentical TCRαβ+/CD19+ cell-depleted hematopoietic stem cell transplantation (HSCT)
Number of subjects: 24
Study 33656536 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA-haploidentical TCRαβ+/CD19+ cell-depleted HSCT
Number of subjects: 24
Study 33656739 — intervention group
Group type: EXPERIMENTAL
Intervention: Peficitinib 50 or 100 mg/day (with dose adjustments allowed)
Number of subjects: 843
Study 33657038 — intervention group
Group type: EXPERIMENTAL
Intervention: Colorectal cancer screening guidelines
Number of subjects: 0
Study 33657038 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin for chemoprevention
Number of subjects: 0
Study 33657038 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality indicators for colonoscopy
Number of subjects: 0